Table of Contents Table of Contents
Previous Page  274 / 812 Next Page
Information
Show Menu
Previous Page 274 / 812 Next Page
Page Background

S270

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

EW444

Sexual side effects in patients treated

with desvenlafaxine: An observational

study in daily practice

B. Navarro

1 ,

, L. Perez

1

, L. Erkoreka

1

, A. Arroita

2

, I. Perez

3

1

Red de Salud Mental de Bizkaia, CSM Barakaldo, Bilbao, Spain

2

Re de Salud Mental de Bizkaia, CSM Barakaldo, Bilbao, Spain

3

Hospital Universitario Cruces, psiquiatría, Barakaldo, Spain

Corresponding author.

Introduction

Sexual function is important for patients’ well-being

but it is a common side effect of SSRI and SNRI, included desven-

lafaxine.

Objectives and aims

Evaluate incidence and characteristics of sex-

ual dysfunction caused by desvenlafaxine in the clinical practice.

Methods

One hundred and thirty-three patients with recently

introduced desvenlafaxine treatment are recruited from Barakldo

and Uribe-Kosta Mental Health Centres in Biscay, Spain. UKU scale

is administered to measure sexual side effects. Statistical analysis

is performed using SPSS v.22.

Results

Sexual dysfunction is observed in 5 patients (3.7%) at

50 and 100mg/d (2 and 3 patients, respectively) desvenlafaxine

doses. Two patients (1.5%) have experimented more than one sex-

ual side effect. Regarding gender differences, the most frequent

sexual dysfunctions are diminished sexual desire (5.5%) and erec-

tile dysfunction (5.5%) in men and orgasmic dysfunction (1.2%) in

women (

P

-values are 0.034; 0.034 and 0.408, respectively). Discon-

tinuation is decided in 60% of patients.

Conclusions

Desvenlafaxine has a well-tolerated sexual side

effect profile in general population. There are some gender-related

differences both in presentation and perception, as it has been

described with other drugs, and this should be taken into account

by prescriptors.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.562

EW445

The novel antipsychotic cariprazine

(RGH-188): State-of-the-art in the

treatment of psychiatric disorders

L. Orsolini

1 , 2 , 3 , 4 ,

, A. Valchera

4 , 5

, D. De Berardis

4 , 6 , 7

,

R. Vecchiotti

1 , 2 , 4

, F. Iasevoli

8

1

Villa San Giuseppe Hospital, Hermanas Hospitalarias, Department

of Psychiatry, Ascoli Piceno, Italy

2

Maastricht University, Department of Psychiatry and

Neuropsychology, Maastricht, Italy

3

University of Hertfordshire, Department of Pharmacy, School of Life

and Medical Sciences, Hatfield, United Kingdom

4

Polyedra, Polyedra Research, Teramo, Italy

5

Villa San Giuseppe Hospital, Heramanas Hospitalarias, Department

of Psychiatry, Ascoli Piceno, Italy

6

Hospital “G. Mazzini”, ASL 4, NHS, Department of Mental Health,

Psychiatric Service of Diagnosis and Treatment, Teramo, Italy

7

University of “G. D’Annunzio”, Department of Neuroscience,

Imaging and Clinical Science, Chieti, Italy

8

Laboratory of Molecular Psychiatry and

Psychopharmacotherapeutics, Section of Psychiatry, Department of

Neuroscience, University School of Medicine “Federico II”, Naples,

Italy

Corresponding author.

Introduction

Cariprazine (RGH-188) is a novel antipsychotic drug

that exerts partial agonismof dopamine D

2

/D

3

receptors with pref-

erential binding to D

3

receptor, antagonism of 5HT

2B

receptors

and partial agonism of 5HT

1A

. Currently, cariprazine is in late-

stage clinical development (phase III clinical trials) in patients with

schizophrenia (S) and in patients with bipolar disorder (BD), as

well as an adjunctive treatment in patients with Major Depressive

Disorder (MDD) and drug-resistant MDD.

Objectives

Cariprazine has completed phase III trials for the acute

treatment of schizophrenia and bipolar mania, phase II trials for the

bipolar depression and MDD whilst it is undergoing phase III trials

as an adjunct to antidepressants.

Aims

The present review aims at proving a comprehensive

summary of the current evidence on the safety, tolerability and

efficacy of cariprazine in the treatment of schizophrenia, BD

(manic/mixed/depressive episode) and MDD.

Methods

A systematic search was conducted on PubMed/

Medline/Scopus and the database on Clinical Trials from inception

until April 2015 by typing a set of specified keywords.

Results

Available evidence seems to support cariprazine efficacy

in the treatment of cognitive andnegative symptoms of schizophre-

nia. Preliminary findings suggest its antimanic activity whilst it

is still under investigation its efficacy in the treatment of bipolar

depression and MDD. Furthermore, the available data seems not to

allow judgements about its antipsychotic potential in comparison

with currently prescribed antipsychotics.

Conclusions

Further studies should be carried out to better inves-

tigate its pharmacodynamic and clinical potential, particularly as

alternative to current antipsychotic drugs.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.563

EW446

Use of inhaled loxapine in acute

psychiatric agitation

S. Ovejero

1 ,

, M. Iza

1

, S. Vallejo

1

, C. Vera

1

, A. Sedano

1

,

R. Álvarez

2

, L. Mata

1

, S. Sánchez-Alonso

1

1

Hospital Universitario Fundación Jiménez Díaz, Psychiatry, Madrid,

Spain

2

Hospital Universitario Rey Juan Carlos, Psychiatry, Móstoles, Spain

Corresponding author.

Objectives

The aimof this work is to study the efficacy of loxapine

inhalation powder on agitated patients in a psychiatric inpatient

unit.

Methods

Nineteen patients sample, with an average age of

39.4 years old, diagnosed with schizophrenia, bipolar disorder or

schizoaffective disorder. Patients inhaled loxapine 10mg, using the

staccato system, when they suffered a psychomotor agitation. The

clinical efficacywasmeasured as a change frombaseline in the Posi-

tive and Negative Syndrome Scale-Excited Component (PANSS-EC)

and in the Young Mania Rating Scale (YMRS) one hour after the

administration of loxapine.

Results

A mean of 9.8 points reduction (22.6 at baseline and 12.7

one hour after the administration) was found on the PANSS-EC

(

t

-test,

P

< .001) and 68.4% of the patients were considered respon-

ders as they obtained a reduction of at least 40% of the basal score.

On 10 of the total of the agitated patients showed an improvement

of the psychomotor excitement, and this allowed the clinicians to

remove the physical restraint; on 6 of the agitated patients the

physical restraint could be avoided during the whole treatment;

and 3 of the patients experienced a reduction of the excitement.

The reduction on PANNS-EC on the latest groupwas not statistically

significant (

t

-test,

P

= .121).

Conclusions

Inhaled loxapine was a non-invasive, rapid and

effective alternative treatment for acute agitation in a psychiatric

inpatient unit. It resulted more effective on mild and moderate

cases; not been significantly effective on the severe cases of agi-

tation.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.564